rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease.
OBJECTIVE: To assess the cost-effectiveness of rhDNase (Pulmozyme(R)) for patients with cystic fibrosis (CF) aged 5 years or more, with mild to moderate lung disease. The review addresses four questions: a) does rhDNase therapy work in the short term?, b) does rhDNase therapy work more effectively i...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 24; no. 6; pp. 415 - 427 |
|---|---|
| Autores principales: | , , , |
| Formato: | research systematic review Journal Article |
| Publicado: |
Wiley-Blackwell
Dec99
|
| Acceso en línea: | Ver este registro en EBSCOhost |